Home  /  Resource Library  /  Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (<65 years) with mantle cell lymphoma (WINDOW-1): a single arm, phase 2 trial

Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (<65 years) with mantle cell lymphoma (WINDOW-1): a single arm, phase 2 trial

Results of a study examining ibrutinib combined with chemoimmunotherapy for first line treatment of MCL. (Abstract only)